Accomplished Pharma R&D leader, Sauri Gudlavalleti joins Sai Life Sciences as Chief Operating Officer
PR94141
HYDERABAD, India, Jan. 19, 2022 /PRNewswire=KYODO JBN/--
Sai Life Sciences, a leading global Contract Research, Development &
Manufacturing Organization [
(CRO-CDMO), today announced the appointment of Sauri Gudlavalleti as its Chief
Operating Officer. Sauri will report to the CEO & Managing Director, Krishna
Kanumuri and drive the company's growth as a new generation, science-driven
organization.
Making the announcement, Krishna Kanumuri said, "I am really excited to
welcome Sauri on board Sai Life Sciences! He brings with him a strong
data-driven, systems approach combined with an innovation mindset and customer
focus. I am confident that this approach will help us build Sai Life Sciences
for greater scale, with high-quality science, speed and operating efficiency as
the key pivots of our growth."
Sauri joins Sai Life Sciences from Dr. Reddy's Laboratories where he was
heading Global R&D and Portfolio Management for small molecule API &
Formulations, encompassing portfolio & strategy, development, technology
transfer, CRO/ CDMO partnerships, IP, regulatory affairs and clinical affairs.
Over his 7-year tenure there, he spearheaded a multifold increase in the R&D
pipeline, significantly globalized the R&D efforts with an impetus on
fast-growing emerging markets and brought about a pioneering transformation in
R&D through data and analytics. More recently, Sauri led the development,
approval and launch of the company's covid portfolio, partnering with global
large pharma innovators, in record time.
Before Dr. Reddy's, Sauri was at McKinsey & Co. for six years where he
successfully delivered on several client engagements with focus on operational
transformation spanning product development, service delivery and manufacturing
operations. Previously, he spent 9 years in the US, working on advanced
technologies at MIT, GE and Qualcomm. He holds 9 US patents and has published
in multiple peer-reviewed journals and conferences. Sauri is a B.Tech from IIT
Madras, an MS from MIT and an MBA from IIM Ahmedabad.
Responding to his appointment, Sauri Gudlavalleti, COO said, "I am
delighted to join Sai Life Sciences at such an exciting time in its journey. In
all my interactions with the various leaders of the company, I have sensed much
excitement and a strong commitment to building a high-quality scientific
company that brings science to life for its customers. This resonates with my
own personal vision of transforming Pharma R&D with innovative technologies,
data and analytics."
Over the past couple of years, the company has undergone an intense phase
of transformation as part of its Sai Nxt initiative [
During this period, it has expanded into new geographies, executed investments
of over US$100M in its capacity and operations, grew its workforce across
locations, consolidated discovery operations from Pune to Hyderabad, and more.
As a result of these efforts, the progress in its trajectory across both its
Discovery and CMC businesses shows a tremendous uptick in the recent months.
About Sai Life Sciences
Sai Life Sciences is a full-service CRO-CDMO [
that works with innovator pharma and biotech companies globally, to accelerate
the discovery, development and commercialisation of complex small molecules.
The company has over 2200 employees across its facilities in India, UK and USA.
Sai Life Sciences is privately held and backed by global investors, TPG Capital
and HBM Healthcare Investments. https://www.sailife.com/
Image: https://mma.prnewswire.com/media/1729548/Sauri_Gudlavalleti.jpg
Logo: https://mma.prnewswire.com/media/1044186/Sai_Life_Sciences_Logo.jpg
Source - Sai Life Sciences
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。